Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins - PubMed (original) (raw)

Comparative Study

. 1996 Mar;148(3):897-909.

Affiliations

• PMID: 8774144
• PMCID: PMC1861728

Comparative Study

Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins

L Borrego et al. Am J Pathol. 1996 Mar.

Abstract

Eosinophils, neutrophils, and mast cells have all been implicated in the pathogenesis of bullous pemphigoid (BP). To comparatively characterize the involvement of these cells in BP, 10 lesional skin biopsy specimens were identified retrospectively and studied for tissue localization of eosinophil, neutrophil, and mast cell granule proteins. Subsequently, multiple skin biopsies of lesions in various developmental stages were obtained from 3 patients with untreated BP. Involved and uninvolved skin specimens were also obtained from 2 patients. Using indirect immunofluorescence, retrospectively identified lesions showed eosinophils and extracellular granule protein deposition prominently in areas of blistering. Evolving lesions showed eosinophil granule protein deposition in all stages but was most marked in early erythematous and prebullous (urticarial) lesions and was minimal in uninvolved skin. Vascular cell adhesion molecule-1, E-selectin, and P-selectin were detected on vessels and very late activation antigen-4 was detected on mononuclear cells and eosinophils by immunoperoxidase staining of lesions. Eosinophil granule proteins were increased in the peripheral blood, urine, and blister fluid. Blister fluids caused increased eosinophil survival that was inhibited by antibodies to interleukin-5 and interleukin-3. Although neutrophil and mast cell infiltration was observed, extracellular granule protein deposition from these cells was minimal except in two specimens. These results demonstrate that eosinophils infiltrate and deposit granule proteins early in the development of BP lesions, that eosinophil-activating cytokines are present in blister fluid, and that eosinophil-selective adhesion molecules are present. These studies strongly support a role for eosinophils in blister formation in BP.

PubMed Disclaimer

Similar articles

• Polymorphic eruption of pregnancy and herpes gestationis: comparison of granulated cell proteins in tissue and serum.
  Borrego L, Peterson EA, Diez LI, de Pablo Martin P, Wagner JM, Gleich GJ, Leiferman KM. Borrego L, et al. Clin Exp Dermatol. 1999 May;24(3):213-25. doi: 10.1046/j.1365-2230.1999.00459.x. Clin Exp Dermatol. 1999. PMID: 10354184
• Evidence for a role of eosinophils in blister formation in bullous pemphigoid.
  de Graauw E, Sitaru C, Horn M, Borradori L, Yousefi S, Simon HU, Simon D. de Graauw E, et al. Allergy. 2017 Jul;72(7):1105-1113. doi: 10.1111/all.13131. Epub 2017 Mar 1. Allergy. 2017. PMID: 28135772
• IL-5 levels in the serum and blister fluid of patients with bullous pemphigoid: correlations with eosinophil cationic protein, RANTES, IgE and disease severity.
  D'Auria L, Pietravalle M, Mastroianni A, Ferraro C, Mussi A, Bonifati C, Giacalone B, Ameglio F. D'Auria L, et al. Arch Dermatol Res. 1998 Jan-Feb;290(1-2):25-7. doi: 10.1007/s004030050272. Arch Dermatol Res. 1998. PMID: 9522998 No abstract available.
• Childhood bullous pemphigoid: a clinicopathologic study and review of the literature.
  Fisler RE, Saeb M, Liang MG, Howard RM, McKee PH. Fisler RE, et al. Am J Dermatopathol. 2003 Jun;25(3):183-9. doi: 10.1097/00000372-200306000-00001. Am J Dermatopathol. 2003. PMID: 12775979 Review.
• Eosinophils in bullous pemphigoid.
  Jones VA, Patel PM, Amber KT. Jones VA, et al. Panminerva Med. 2021 Sep;63(3):368-378. doi: 10.23736/S0031-0808.20.03997-X. Epub 2020 Jun 12. Panminerva Med. 2021. PMID: 32536149 Review.

Cited by

• Systemic Implications of Bullous Pemphigoid: Bridging Dermatology and Internal Medicine.
  Mashima E, Saito-Sasaki N, Sawada Y. Mashima E, et al. Diagnostics (Basel). 2024 Oct 12;14(20):2272. doi: 10.3390/diagnostics14202272. Diagnostics (Basel). 2024. PMID: 39451595 Free PMC article. Review.
• Targeting type 2 inflammation in bullous pemphigoid: current and emerging therapeutic approaches.
  Toh WH, Lee HE, Chen CB. Toh WH, et al. Front Med (Lausanne). 2023 Aug 8;10:1196946. doi: 10.3389/fmed.2023.1196946. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37614956 Free PMC article. Review.
• The relevance of complement in pemphigoid diseases: A critical appraisal.
  Papara C, Karsten CM, Ujiie H, Schmidt E, Schmidt-Jiménez LF, Baican A, Freire PC, Izumi K, Bieber K, Peipp M, Verschoor A, Ludwig RJ, Köhl J, Zillikens D, Hammers CM. Papara C, et al. Front Immunol. 2022 Aug 16;13:973702. doi: 10.3389/fimmu.2022.973702. eCollection 2022. Front Immunol. 2022. PMID: 36059476 Free PMC article. Review.
• Insights Into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms.
  Cole C, Vinay K, Borradori L, Amber KT. Cole C, et al. Front Immunol. 2022 Jul 7;13:912876. doi: 10.3389/fimmu.2022.912876. eCollection 2022. Front Immunol. 2022. PMID: 35874745 Free PMC article. Review.
• A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets.
  Afarideh M, Borucki R, Werth VP. Afarideh M, et al. J Clin Med. 2022 May 18;11(10):2856. doi: 10.3390/jcm11102856. J Clin Med. 2022. PMID: 35628982 Free PMC article. Review.

References

1. 1. J Clin Invest. 1973 Jul;52(7):1779-87 - PubMed
2. 1. J Allergy Clin Immunol. 1994 Dec;94(6 Pt 2):1183-8 - PubMed
3. 1. J Invest Dermatol. 1975 Aug;65(2):217-9 - PubMed
4. 1. J Lab Clin Med. 1975 Nov;86(5):733-40 - PubMed
5. 1. N Engl J Med. 1978 Feb 23;298(8):417-21 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central

• Medical

  • MedlinePlus Health Information